Swedish Biotech Update -ads

Karolinska Innovations AB
Karolinska Innovations AB (KIAB) manages and commercializes the intellectual property of Karolinska Institutet's researchers and entrepreneurs. Karolinska Innovations AB acts as a catalyst for their commercial development into innovative new products and therapies for the consumer market.

KIAB reviews approximately 100 new inventions every year. Selected inventions are thereafter commercialized either by starting up companies to develop the intellectual property, or by out-licensing to pharmaceutical/biotech companies.

During the last year, KIAB has formed 10 new biotech companies. Among these are companies covering the fields of gene therapy, cancer and gene chip technology. KIAB helps the inventor in the process from patenting the scientific discovery to writing a business plan and finding potential investors.

Karolinska Innovations AB's current portfolio consists of over 50 projects spanning the fields of cancer, cardiovascular diseases, CNS diseases, gene therapy, genomics, inflammation, as well as other projects concerning Biotechnology nd Medical Devices.

Karolinska Innovations AB share the profits obtained through commercialization of KIAB’s IP with the respective researchers. KIAB's own profits are reinvested into commercializing new innovations.

Tripep
Tripep's business mission is to develop and commercialize pharmaceuticals based primarily on the company's patented technologies.

The project that has developed the furthest is GPG®, a potential new inhibitory agent for HIV. GPG attacks the virus through a new mechanism of action, called protein polymerization inhibition (PPI). Owing to this unique mechanism of action, the substance has proved effective even in inhibiting growth of multiresistant strains of HIV. With its PPI technology, Tripep can develop additional candidate drugs for treating other chronic diseases, including substances that inhibit the hepatitis C virus and the inflammation protein TNF-alpha.

Tripep second technology platform is called RAS, Re-directing Antibody Specificity. RAS imply that and directs an antibody towards a new target (or antigen). The RAS peptide, steers existing antibodies specifically to the new predetermined target such as antigens involved in infectious diseases, toxin related antigens or antigens specific for tumors or auto immune diseases.

Tripep has also inlicensed another technology designated PVK - Parvo Virus Kapsid technology. The applications are areas where the inhibition of the growth of hematopoetic or endothelial cells are wanted and Tripep has identified three primary areas of interest. Polycythemia vera, Inhibition of angiogenesis in solid tumors and prior to bone marrow transplantation.

Biolin Medical
Biolin Medical is a research and development based venture capital company creating value growth in advanced technology companies within biotechnology, medical technology and related areas. Biolin develops innovations into commercial enterprises through operational owner involvement based on unique competence and the support of a comprehensive network.

As a supplement to its business concept, Biolin has developed a concept that forms the basis of daily and long-term work with existing and potential projects. The concept is the core of Biolin's value-creating process and comprises intellectual capital such as competence, experience, working methods and values as well as structural capital in the form of processes, procedures, networks and relations. Biolin's views of how new projects are identified, as well as how they are developed and finally divested, are accommodated within the framework of the concept.
The collective experience behind Biolin demonstrates the need for driving development work as directly and simply as possible. Biolin's organization and network includes access to crucial competence and experienced individuals who give the portfolio companies concrete opportunities to work their way through the required development phases more quickly and at a reduced risk to achieve a commercial success.

Biolin's project portfolio currently consists of participation in the companies AlcoDia, Biovator, BST Blood Saving Technologies, Boule Diagnostics, Cavidi Tech, Integration Diagnostics, Q-Sense and Sinterkil. Biolin is owned and financed by approximately 150 institutional and private shareholders.